Section Arrow
Quote
JAZZ.NASDAQ
- Jazz Pharmaceuticals plc
Quotes are at least 15-min delayed:2026/07/17 04:57 EDT
Pre Market
Last
 240
-2.18 (-0.90%)
Bid
222
Ask
253.25
High 242.18 
Low 239.65 
Volume 6 
Regular Hours (Closed)
Last
 242.18
+2.86 (+1.20%)
Day High 
243.21 
Prev. Close
239.32 
1-M High
250.49 
Volume 
430.68K 
Bid
222
Ask
253.25
Day Low
238 
Open
238.54 
1-M Low
220.74 
Market Cap 
15.03B 
Currency 美元 
P/E 2,175.64 
%Yield -- 
10-SMA 242.62 
20-SMA 236.28 
50-SMA 233.19 
52-W High 250.49 
52-W Low 105 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.11/17.64
Enterprise Value
19.41B
Balance Sheet
Book Value Per Share
72.15
Cash Flow
Cash Flow Yield
0.09
Income Statement
Total Revenue
4.27B
Operating Revenue Per Share
60.40
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc0.1477+0.0332+29.00%-- 
Pre Market 0.1307 -0.017 -11.51%
ATAIAtaiBeckley Inc7.15+1.79+33.40%-- 
Pre Market 7.1 -0.05 -0.70%
KAPAKairos Pharma Ltd.0.3399+0.0219+6.89%-- 
Pre Market 0.2943 -0.0456 -13.42%
RXRXRecursion Pharmaceuticals3.02-0.29-8.76%-- 
Pre Market 2.965 -0.055 -1.82%
IOVAIovance Biotherapeutics4.66-0.08-1.69%-- 
Pre Market 4.6235 -0.0365 -0.78%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.